Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: implications for immunotherapy (original) (raw)
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome
toni molina
Blood, 2009
View PDFchevron_right
Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 In Hodgkin's Lymphoma Cells Mediates Up-Regulation of CCL20 and the …
Lee Machado
American Journal of …, 2008
View PDFchevron_right
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells
Lee Machado
The American journal of pathology, 2008
View PDFchevron_right
Epstein–Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma
oscar eduardo jimenez
Cancer Immunology, Immunotherapy
View PDFchevron_right
Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
Justyna Wos
PLoS ONE, 2013
View PDFchevron_right
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance
Barbara Sherry
Haematologica, 2012
View PDFchevron_right
Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells
Merica Glavina-durdov
Medical Science Monitor, 2016
View PDFchevron_right
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Wael Gamal
Blood Advances
View PDFchevron_right
The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma
aysun senturk
Clinical Lymphoma Myeloma and Leukemia, 2020
View PDFchevron_right
Analysis of Interleukin-27 (EBI3/p28) Expression in Epstein-Barr Virus- and Human T-Cell Leukemia Virus Type 1-Associated Lymphomas
Robert Kastelein
The American Journal of Pathology, 2005
View PDFchevron_right
Epstein-Barr virus in the pathogenesis of Hodgkin's disease
Riccardo Dolcetti
Biomedicine & Pharmacotherapy, 1998
View PDFchevron_right
Epstein-Barr virus, cytokines, and inflammation: A cocktail for the pathogenesis of Hodgkin's lymphoma?
Gulfaraz Khan
Experimental Hematology, 2006
View PDFchevron_right
Expression of CCL17 and CCL22 by latent membrane protein 1‐positive tumor cells in age‐related Epstein–Barr virus‐associated B‐cell lymphoproliferative disorder
takashi takashi
Cancer Science, 2008
View PDFchevron_right
Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease
Teresa Frisan
Blood, 1995
View PDFchevron_right
Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact
Fernanda Metrebian
Scientific Reports, 2017
View PDFchevron_right
How Epstein-Barr Virus “Manipulates” The Tumoral Microenvironment in Hodgkin Lymphoma?
Ana-Maria Bordea
Internal Medicine, 2019
View PDFchevron_right
Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function
Walid Mourad
British Journal of Cancer, 1999
View PDFchevron_right
Loss of P16 Protein Expression and Its Association with Epstein‐Barr Virus LMP‐1 Expression in Hodgkin's
Irshaid I Irshaid
Iran J Cancer Prevention, 2013
View PDFchevron_right
Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
manal saber
Journal of Immunology Research
View PDFchevron_right
Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection
María Gabriela Vera Lozada
View PDFchevron_right
A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells
Cliona Rooney
Cancer Gene Therapy, 2004
View PDFchevron_right
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus � Hodgkin's Disease
Laura Aguilar
View PDFchevron_right
Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
D. Gottlieb
Clinical Cancer Research, 2013
View PDFchevron_right
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
Madina Sukhanova
Blood Advances, 2023
View PDFchevron_right
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion
John Gribben
Haematologica
View PDFchevron_right
Loss of P16 Protein Expression and Its Association with Epstein-Barr Virus LMP-1 Expression in Hodgkin's Lymphoma
Irshaid I Irshaid
View PDFchevron_right
Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
Eleftheria Hatzimichael
Biology
View PDFchevron_right
The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good
José Luis Solórzano
Cancers, 2022
View PDFchevron_right
CD4+ T‐cell responses to Epstein–Barr virus (EBV) latent membrane protein 1 in infectious mononucleosis and EBV‐associated non‐Hodgkin lymphoma: Th1 in active disease but Tr1 in remission
annaleen louwes
British Journal of Haematology, 2007
View PDFchevron_right
Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease
J. Samol
Blood, 1996
View PDFchevron_right